












622Use of a novel hybrid vascular graft for sutureless
revascularization of the renal arteries during open
thoracoabdominal aortic aneurysm repair
Roberto Chiesa, MD, Andrea Kahlberg, MD, Daniele Mascia, MD, Yamume Tshomba, MD,
Efrem Civilini, MD, and Germano Melissano, MD, Milan, Italy
Objective: The aim of this study was to assess the safety and short-term effectiveness of a novel hybrid vascular graft used
to address renal revascularization during open thoracoabdominal aortic aneurysm (TAAA) repair, performing a sutureless
distal anastomosis.
Methods: Between 2012 and 2013, 25 patients (16 men; mean age, 66 6 8 years) underwent revascularization of one
(24 patients) or both (one patient) renal arteries with the Gore Hybrid Vascular Graft (GHVG; W. L. Gore and As-
sociates, Flagstaff, Ariz) during open TAAA repair. Speciﬁc indications included remote location of the ostium of the
renal artery, severe atherosclerotic wall degeneration, focal dissection, and stenosis. All surviving patients underwent
computed tomography angiography and follow-up visit at 1 month. Preoperative characteristics, intraoperative data, and
short-term results were compared with those of 49 concurrent TAAA patients operated on within the same period by
standard renal revascularization (SRR) techniques.
Results: All GHVG target renal vessels (26 of 26) were successfully revascularized without technical concerns.
No signiﬁcant differences were found between GHVG and SRR groups in preoperative and intraoperative data, except
for a relative prevalence of aortic dissection (28% vs 6%; P [ .026) and renal artery stenosis (44% vs 12%; P [ .003) in
the GHVG group and for intraoperative renal bare stenting that was predominantly used in the SRR group (12% vs 28%;
P [ .036). The 30-day mortality was 4% in both groups. Postoperative acute renal failure (doubling of creatinine
level and creatinine level >3.0 mg/dL) occurred in two GHVG patients (8%) and seven SRR patients (14%; P [ NS).
Perioperative peak decrease of estimated glomerular ﬁltration rate was lower in the GHVG group (26 6 18 mL/min/
1.73 m2 vs 37 6 22 mL/min/1.73 m2; P[ .034). At 1-month computed tomography angiography, renal artery patency
was 92% for the GHVG vessels, 91% for the contralateral to GHVG renal vessels, and 92% for the SRR group arteries. No
GHVG-related complications requiring reintervention or cases of new-onset renal failure requiring dialysis were observed
at follow-up.
Conclusions: Renal revascularization during open TAAA repair by the GHVG with distal sutureless anastomosis is
feasible, especially in cases of aortic dissection, remote location of the renal vessel, and severe atherosclerotic disease of the
ostium. Short-term results are satisfactory, at least comparable to those of SRR. Larger series and longer follow-up are
needed to assess clinical advantages and durability of this new device. (J Vasc Surg 2014;60:622-30.)Although great strides in morbidity and mortality
reduction have been made in the surgical treatment of
thoracoabdominal aortic aneurysm (TAAA),1 perioperative
acute renal dysfunction still complicates up to 70% of these
procedures even in the most specialized centers.2 The clin-
ical consequences of postoperative renal impairment are
noteworthy: its occurrence has been shown to be the stron-
gest predictor of early mortality and to be associated with
permanent long-term chronic kidney disease.3,4
Multiple etiopathologic factors are supposed to be
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://dx.doi.org/10.1016/j.jvs.2014.03.256important are deﬁnitely the time of renal ischemia during
artery reattachment and the associated atherosclerotic renal
vessel disease, such as ostial stenosis or dissection. These
factors account for a signiﬁcant increase in technical difﬁ-
culty, prolonged time of anastomosis, and increased global
risk of intraoperative renal injury.
Covered self-expanding stents are being used to
perform “sutureless anastomoses” on visceral aortic
branches (including the renal arteries) during debranching
procedures, obviating the need for technically demanding
vessel exposure and anastomoses, thereby reducing the
duration of ﬂow interruption and simplifying the perfor-
mance of complex aortic repair.5 Lachat and colleagues
named this method VORTEC (Viabahn Open Revasculari-
zation TEChnique), as they used a “standard” covered stent
graft (Viabahn; W. L. Gore and Associates, Flagstaff, Ariz).
The Gore Hybrid Vascular Graft (GHVG; W. L. Gore
and Associates) is a novel expanded polytetraﬂuoroethylene
(ePTFE) vascular prosthesis that includes a nitinol-
reinforced self-expanding section at one of its extremities,
allowing a “sutureless” endovascular anastomosis. In this
study, we report our initial experience with this graft for
Table I. Demographics and preoperative risk factors of
the 25 Gore Hybrid Vascular Graft (GHVG) and the
concurrent 49 standard renal revascularization (SRR)
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 3 Chiesa et al 623renal revascularization during TAAA open repair to assess
the safety and short-term results of this technique compared
with standard renal revascularization (SRR) strategies.patients
Variables
GHVG
patients SRR patients P
Total 25 49
Gender, male 16 (64) 39 (80) NS
Age, years 66.0 6 8.4 65.0 6 10.1 NS
Etiology
Atherosclerotic/degenerative 17 (68) 42 (86) NS
Chronic type B dissection 7 (28) 3 (6) .026
Para-anastomotic
pseudoaneurysm
1 (4) 0 (0) NS
Connective tissue disorder 0 (0) 4 (8) NS
Principal comorbidities
Hypertension 22 (88) 44 (90) NS
Diabetes mellitus 6 (24) 9 (18) NS
Dyslipidemia 13 (52) 27 (55) NS
Active smoking 7 (28) 14 (29) NS
COPD 17 (68) 35 (71) NS
Extracardiac arteriopathy 10 (40) 12 (24) NS
Coronary artery disease 7 (28) 9 (18) NS
Cerebrovascular disease 6 (24) 8 (16) NS
CKD stages
Stage 1 7 (28) 15 (31) NS
Stage 2 10 (40) 20 (41) NS
Stage 3 6 (24) 10 (20) NS
Stage 4 2 (8) 4 (8) NS
Stage 5 0 (0) 0 (0) NS
ASA score 3.6 6 0.5 3.5 6 0.5 NS
Classiﬁcation of aneurysmsa
TAAA extent I 0 (0) 2 (4) NS
TAAA extent II 10 (40) 16 (33) NS
TAAA extent III 8 (32) 15 (31) NS
TAAA extent IV 7 (28) 14 (29) NS
TAAA extent V 0 (0) 2 (4) NS
Aneurysm maximum diameter,
mm
67 6 21 68 6 14 NS
Pararenal aortic diameter, mm 60 6 19 65 6 13 NS
Associated renal artery stenosis 11 (44) 6 (12) .003
ASA, American Society of Anesthesiologists; CKD, chronic kidney disease;
COPD, chronic obstructive pulmonary disease; NS, not signiﬁcant; TAAA,
thoracoabdominal aortic aneurysm.
Continuous data are presented as mean 6 standard deviation and cate-
gorical data as number (%).
aAccording to the Crawford-Saﬁ revised TAAA extent classiﬁcation.METHODS
We analyzed a single-center series of 25 consecutive
patients who underwent elective TAAA open repair,
including at least one renal revascularization with the
GHVG, between September 2012 and November 2013.
During the same period, 49 other patients were submitted
to TAAA open repair with SRR techniques because the
GHVG was deemed to be contraindicated or not necessary
by the operating surgeon.
Data of both groups were prospectively collected in an
electronic database. Informed consent of the patient was
obtained in all cases. All survivors were followed up
1 month after the operation by means of computed tomog-
raphy angiography (CTA) and ofﬁce visit.
Demographics and preoperative risk factors of patients
included in the analysis are reported in Table I. Patients
were stratiﬁed into the ﬁve chronic kidney disease stages
according to the National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative guidelines.6
All patients underwent preoperative CTA within
1 month before the procedure. Patients were stratiﬁed by
aneurysm extension to the Crawford-Saﬁ revised classiﬁca-
tion. Aneurysm size was determined on the basis of CTA
three-dimensional reconstructions by use of the cross-
sectional diameter of the aortic centerline. In the GHVG
group, all patients had two functioning kidneys with a sin-
gle patent renal artery at preoperative CTA, for a total of
50 patent renal arteries in this group. In the SRR group,
43 patients had a bilaterally patent renal artery, four pa-
tients had only one functioning kidney with a single patent
renal artery, and two patients had multiple (double) patent
renal arteries for the same kidney, for a total of 96 patent
renal arteries in this group. Renal artery stenosis was
deﬁned as a >50% lesion as documented by CTA.
Intraoperative variables were recorded and are listed in
Table II. Total renal ischemia time was deﬁned as the dura-
tion from ﬁrst aortic cross-clamping to complete bilateral
renal revascularization. Isothermic renal distal perfusional
time was considered the duration of aortic cross-clamping,
with working left-sided heart bypass providing retrograde
blood perfusion to the kidneys. Cold renal perfusional time
was deﬁned as the duration of cold selective renal artery
perfusion after opening of the visceral aortic segment.
Morbidity and mortality were recorded (Table III).
Serum creatinine concentration was measured the day
before the operation (baseline value) and postoperatively
on a daily basis. Acute renal failure was deﬁned as both a
doubling of the serum creatinine level and an absolute
value above 3.0 mg/dL.7 Glomerular ﬁltration rate was
estimated (eGFR) by the Chronic Kidney Disease Epidemi-
ology Collaboration formula (expressed as mL/min/
1.73 m2).8 Perioperative peak decrease of eGFR was calcu-
lated as the difference from the preoperative eGFR valueand the lowest eGFR value measured during the postoper-
ative period.
All CTAs performed at 1 month after the operation
were carefully reviewed to ascertain patency of the renal
vessels and of the implanted grafts and to identify graft
migration, stenosis, kinking or twisting, stent fractures,
and instances of bleeding or renal infarctions.
Continuous variables are presented as mean6 standard
deviation; those with non-normal distributions are pre-
sented as median (interquartile range), and discrete vari-
ables are reported as number (and proportion) of
patients. To compare preoperative clinical characteristics
(Table I), intraoperative surgical data (Table II), and post-
operative outcomes (Table III) including cumulative
Table III. Short-term outcomes of the Gore Hybrid








2.0 6 1.7 2.2 6 1.1 NS
Perioperative peak decrease
of eGFR, mL/min/1.73 m2
26 6 18 37 6 22 .034
Acute renal failure 2 (8) 7 (14) NS
Temporary hemodialysis 1 (4) 1 (2) NS
Dialysis at discharge 0 (0) 1 (2) NS
Respiratory insufﬁciency 12 (48) 22 (45) NS
Paraplegia/paraparesis 2 (8) 6 (12) NS
Ischemic bowel 0 (0) 2 (4) NS
Stroke 0 (0) 0 (0) NS
Cerebral hemorrhage 0 (0) 1 (2) NS
Cardiac complication 3 (12) 8 (16) NS
Bleeding requiring
reintervention
1 (4) 2 (4) NS
ICU time, days 2 (1-4) 2 (1-3) NS
LOS, days 7 (5-12) 9 (7-11) NS
Operative mortality 0 (0) 1 (2) NS
In-hospital mortality 1 (4) 2 (4) NS
30-day mortality 1 (4) 2 (4) NS
eGFR, Estimated glomerular ﬁltration rate; ICU, intensive care unit;
LOS, length of stay; NS, not signiﬁcant.
Continuous data are presented as mean 6 standard deviation and median
(interquartile range), and categorical data are presented as number (%).
Table II. Intraoperative details of the Gore Hybrid
VascularGraft (GHVG) and standard renal revascularization








CSF drainage 23 (92) 39 (80) NS
LHBP 21 (84) 36 (73) NS
Intercostal/lumbar artery
reimplantation
17 (68) 28 (57) NS
Renal perfusion (4C
Custodiol)
25 (100) 49 (100) NS
CT/SMA perfusion
Normothermic blood 21 (84) 36 (73) NS
4C Lactated Ringer
solution
4 (16) 13 (26) NS
Total surgical time,
minutes
272 6 87 285 6 80 NS
Total renal ischemia time,
minutes




25 6 15 25 6 14 NS
Cold renal perfusional
time, minutes
28 6 13 34 6 10 .031
Urine output during
operation, mL
1485 6 862 1654 6 1025 NS
Intraoperative losses 4451 6 2796 4890 6 3466 NS
Transfusion requirements,
mL
Packed red blood cells 1104 6 693 1072 6 748 NS












22 (44) 69 (72) .001
Presewn multibranched
graft
0 (0) 14 (15) .002
Conventional aortorenal
bypass
2 (4) 13 (13) NS
Left 2 (100) 13 (100) d
Right 0 (0) 0 (0) d
GHVG 26 (52) d d
Left 17 (65) d d
Right 9 (35) d d
Renal stenting (non-GHVG
vessel)
6 (12) 27 (28) .036
Renal endarterectomy 0 (0) 2 (2) NS
CSF,Cerebrospinal ﬂuid;CT, celiac trunk; LHBP, left-sided heart bypass;NS,
not signiﬁcant; SMA, superior mesenteric artery.
Continuous data are presented as mean 6 standard deviation and cate-
gorical data as number (%).
aOf the 49 SRR patients, preoperatively 43 patients had a bilaterally patent
renal artery, four patients had a single patent renal artery, and two patients
had multiple (double) patent renal arteries for the same kidney.
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SRR group, two-tailed Fisher exact test and c2 test were
used in the case of categorical variables, and two-tailedpaired t-test (for normally distributed variables) and the
Kruskal-Wallis test (for non-normally distributed variables)
were used in the case of continuous variables. A two-tailed
P value < .05 was considered signiﬁcant.
Device description, indications, and surgical tech-
nique. We previously reported our standard surgical tech-
niques and outcomes for TAAA open repair and renal
vessel management.9
The GHVG received U.S. Food and Drug Administra-
tion approval in March 2010 and obtained the CE Mark in
July 2012. This device is currently commercially available
in the United States, Europe, Russia, and a few Middle
Eastern countries. It is an ePTFE vascular prosthesis that
has a distal section reinforced with nitinol (Fig 1). The
nitinol-reinforced section is partially constrained to allow
easy insertion and deployment into a vessel. Its lumen is
continuous with the CARMEDA BioActive Surface
(Medtronic, Minneapolis, Minn), consisting of a stable
covalently bonded, reduced molecular weight heparin of
porcine origin. An embedded low-permeability ﬁlm pro-
vides a barrier to ultraﬁltration. The graft is available with
a nitinol-reinforced section length of 5 and 10 cm and
diameter of 6, 7, 8, and 9 mm.
In this initial experience, our indication for the use of
the GHVG was generally limited to renal vessels that
were not considered suitable for inclusion in an aortic patch
because of their anatomic location or the poor quality of
the surrounding aortic wall. We favored the GHVG over
a standard aortorenal bypass graft in cases of anatomically
Fig 1. The Gore Hybrid Vascular Graft (GHVG). ePTFE, Expanded polytetraﬂuoroethylene.
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of severe atherosclerotic disease of the proximal tract of the
renal artery (including the presence of highly calciﬁed or
disrupted plaque, critical stenosis, or local dissection).
The choice to use the GHVG was guided by the intention
to decrease technical complexity and duration of the distal
anastomosis, to reduce accidental damage to the arterial
wall, concurrently to treat stenotic or dissected arteries,
and to prevent early kinking of bypassed renal vessels dur-
ing viscera derotation.
Sizing of the nitinol-reinforced section was performed
with a 10% to 20% oversizing compared with the diameter
of the target renal vessel as measured at preoperative CTA
and conﬁrmed by intraoperative ﬁndings. The distance be-
tween the origin and the bifurcation of the renal artery was
always measured at preoperative CTA to avoid uninten-
tional coverage of renal artery branches during GHVG
deployment.
Contraindications to use of the GHVG included target
renal artery diameter <5 mm or >8 mm, anomalous major
collaterals of the target renal artery originating in its prox-
imal tract, and severe stenosis of the distal tract of the
target renal artery.
With the patient on cerebrospinal ﬂuid drainage, placed
in a right lateral decubitus position, thoracophreno-
laparotomy is performed and the thoracoabdominal aorta
is exposed following our standard surgical technique.9
After institution of left-sided heart bypass, the proximal
anastomosis is performed, and critical intercostal arteries
are reattached by a sequential clamping technique. The
distal clamp is then moved below the renal arteries, and
the visceral aorta is opened. Visceral normothermic hemo-
perfusion is then delivered by the pump with 9F irrigation-
occlusion catheters (LeMaitre Vascular, Burlington, Mass)
into the celiac trunk and the superior mesenteric artery
(400 mL/min). Selective perfusion of the renal arteries is
performed with cold (4C) crystalloid solution enriched
with histidine-tryptophan-ketoglutarate (Custodiol).10
Visceral arteries that are not deemed to require a separate
reattachment are usually ﬁrst reimplanted by means of a
Carrel patch. The distal aortic anastomosis is then
performed, and the aortic clamps are removed.After identiﬁcation of the GHVG target renal vessel,
the perfusion catheter is temporarily removed. A ﬂexible
steerable J-tip guidewire (usually 0.035 inch) is inserted
into the renal artery. The constrained stented segment of
the GHVG is gently placed into the artery for 2 to 3 cm,
with respect to the distances measured at preoperative
CTA, with the deployment line facing upward. The stent
is released, pulling the deployment line parallel to the
vascular graft section (Fig 2). Care must be taken to hold
it ﬁrmly in place during this maneuver. Stent post-
dilation is performed in all cases after GHVG distal
segment deployment by a 5- to 6-mm noncompliant
balloon advanced on the guidewire through the conduit.
The cold renal perfusion catheter is then immediately rein-
serted into the graft to reduce renal ischemia. The GHVG
is then sewn in place with at least four single circumferen-
tial monoﬁlament polypropylene stitches. Finally, the prox-
imal anastomosis to the main aortic graft is completed in
the usual fashion after the proximal unstented section of
the graft is cut at the proper length.
After blood ﬂow restoration, protamine is administered
to completely reverse heparin. Red blood cells, platelets,
and plasma transfusions are aggressively used to correct
severe thrombocytopenia and coagulation derangements.
Anastomoses are carefully checked for bleeding and rein-
forced when needed. Mild initial bleeding from ePTFE
needle holes usually resolved spontaneously after a few mi-
nutes. In case of major suture hole bleeding, hemostasis is
obtained by manual compression with surgical gauze and
oxidized cellulose pads.
Antiplatelet therapy (usually aspirin) is routinely initi-
ated by the third postoperative day if it is not contraindi-
cated. Double antiplatelet therapy (adding ticlopidine or
clopidogrel) is then started by the tenth postoperative
day and continued after discharge for at least 1 month.
RESULTS
In the GHVG group, all patients presented two patent
renal arteries at preoperative CTA, for a total of 50 renal
arteries to be revascularized during TAAA open repair.
A >50% stenosis at the ostium of 11 renal vessels was
detected at preoperative CTA; in another 28 arteries,
Fig 2. Sequence of Gore Hybrid Vascular Graft (GHVG) deployment during distal “sutureless” anastomosis of a left
aortorenal bypass.A,During insertionof the device, the origin of the renal artery is suspendedwith separate stitches (yellow
arrows). With the GHVG ﬁrmly held, the stent is released by pulling the deployment line (blue arrow). B, After release of
the nitinol-reinforced section, the device is ﬁxed, sewing the circumferential stitches (arrows). C, Final result after aortic
reconstruction and bilateral renal revascularization with two GHVGs. LRA, Left renal artery; RRA, right renal artery.
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was found. Twenty-six renal arteries were revascularized
with the GHVG (17 left and nine right) and 24 with stan-
dard surgical techniques (22 by means of Carrel patch
reimplantation and two by means of conventional aortore-
nal bypass). Indications for the use of the GHVG included
intraoperative detection of a remote location of the ostium
of the renal artery (20 cases; 77%), severe atherosclerotic
wall degeneration or dissection (23 cases; 88%), and renal
artery stenosis (seven cases; 27%).
No signiﬁcant differences were found between the
GHVG group and the SRR group in preoperative charac-
teristics (Table I), except for a relative prevalence of aortic
dissection (28% vs 6%; P ¼ .026) and renal artery stenosis
(44% vs 12%; P ¼ .003) in the GHVG group.
Intraoperative data are summarized in Table II. Surgi-
cal techniques for renal revascularization differed signiﬁ-
cantly between the GHVG and SRR groups, resulting ina relative prevalence of Carrel patch reimplantation and
use of presewn multibranched graft in the SRR group
(44% vs 72%; P ¼ .001, and 0% vs 15%; P ¼ .002,
respectively).
All intended target renal vessels were treated without
technical concerns with the GHVG. No signiﬁcant bleeding
from ePTFE needle holes or from the graft anastomoses was
observed. Total surgical and total renal ischemia times were
slightly shorter in the GHVG group compared with SRR,
but this difference did not reach statistical signiﬁcance
(272 6 87 minutes vs 285 6 80 minutes; P ¼ NS; and
536 23minutes vs 596 16minutes; P¼NS, respectively).
Cold renal perfusional time was signiﬁcantly shorter in
the GHVG group (28 6 13 minutes vs 34 6 10 minutes;
P ¼ .031).
No adjunctive unplanned endovascular or surgical pro-
cedures were required on the GHVG-treated vessels.
Before revascularization, a balloon-expandable stent was
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GHVG group (contralateral to the GHVG target vessel)
and in 27 renal arteries in the SRR group, resulting in a sig-
niﬁcant prevalence of renal artery bare stenting in the SRR
group (12% vs 28%; P ¼ .036).
The 30-day mortality was 4% in both groups
(Table III). In the GHVG group, one patient died on post-
operative day 6 of myocardial infarction. In the SRR group,
one patient died intraoperatively of acute ascending aortic
dissection with left main coronary artery occlusion; another
patient died on postoperative day 26 of multiorgan failure.
No signiﬁcant differences were found between groups
in regard to perioperative complications. Acute renal failure
occurred in two GHVG patients. The ﬁrst patient experi-
enced perioperative paraparesis; postoperative creatinine
level reached 4.51 mg/dL but returned to 2.87 mg/dL
after 6 days and did not require dialysis; 1-month CTA
revealed occlusion of the right aortorenal conventional
bypass. The second patient had a history of bilateral renal
polycystic disease, with a baseline creatinine value of
3.86 mg/dL; he required temporary dialysis during the
ﬁrst and second postoperative days and then returned to
baseline renal function; 1-month CTA revealed regular
patency of both renal arteries. The rate of acute renal fail-
ure showed an increased trend in the SRR group (14%)
compared with the GHVG group (8%), but this difference
was not statistically signiﬁcant. Perioperative peak decrease
of eGFR was signiﬁcantly lower in the GHVG group (266
18 mL/min/1.73 m2 vs 37 6 22 mL/min/1.73 m2; P ¼
.034).
Follow-up CTA was available in 24 GHVG patients (all
patients except for the one who died perioperatively),
including 25 renal arteries revascularized with the GHVG
and 23 revascularized with standard techniques. In the
SRR group, only 32 follow-up CTAs were available for
analysis, for a total of 62 revascularized renal arteries. No
signiﬁcant stenosis, migration, stent fracture, kinking, or
twisting of the GHVG was observed. No areas of renal
infarction were observed in patients with patent aortorenal
grafts. Patency rates were 92% (23 of 25) for the aortorenal
grafts performed with the GHVG, 91% (21 of 23) for the
contralateral renal arteries revascularized with standard
techniques in the same group (one renal artery occlusion
after Carrel patch reimplantation and one occlusion of con-
ventional aortorenal bypass), and 92% (57 of 62) for revas-
cularized renal vessels in the SRR group. No renal
complications requiring reintervention or cases of new-
onset renal failure requiring dialysis were reported at
follow-up in both groups.
DISCUSSION
Open repair of thoracoabdominal aortic disease is dura-
ble, with well-deﬁned and acceptable long-term survival.11
Its applicability covers the widest range of aortic anatomies
as well as different underlying aortic diseases, including dis-
sections and connective tissue disorders. Despite speciﬁc
renal protection strategies, acute kidney dysfunction sec-
ondary to ischemia-reperfusion injury remains one of themost serious complications of TAAA open repair, with
about 6% to 10% of patients requiring postoperative hemo-
dialysis.3,12 If lesser grades of postoperative kidney injury
are also considered, an elevation in baseline creatinine level
up to 50% may be observed in more than 70% of patients.2
Most important, in a recent study reviewing all the pub-
lished data of the past decade (2000-2010) for open
TAAA surgical repair,1 the rate of postoperative renal com-
plications did not seem to decrease compared with a similar
review published in 1995, regardless of medical and surgi-
cal advances.13
Major causes of intraoperative renal damage include
temporary ischemia during aortic cross-clamping and
visceral vessel repair, arterial embolism, and stenosis or
dissection of the reattached renal vessel.14-16 These harmful
mechanisms are known to develop especially when the
quality of the arterial wall is poor, with severe atherothrom-
botic vessel degeneration, and when the surgical reattach-
ment of the renal artery is demanding because of its
anatomic location.
Traditional methods of renal artery revascularization
during TAAA open repair include direct reattachment on
the aortic graft with the inclusion technique described by
Crawford et al17 (usually together with other visceral ves-
sels, or even by direct single-vessel reimplantation) and
the use of a single aortorenal bypass.
The inclusion in a visceral aortic patch (VAP) is rela-
tively simple and has the advantage of decreasing the global
number of anastomoses and the duration of organ
ischemia. However, a fragile aortic wall can cause difﬁ-
culties with bleeding control, the suture line may become
too long in case of considerable distances between the
visceral arterial ostia, and the aortic patch tissue may result
in subsequent aneurysmal degeneration in time.18 The last
one is considered the main disadvantage of the VAP tech-
nique; we previously demonstrated that a large VAP
including four visceral vessels is associated with VAP aneu-
rysm formation18 and that consequent corrective surgery is
associated with high morbidity and mortality.19
To reduce the VAP size, separate reattachment of
distant visceral vessels, namely, the left renal artery, may
be employed, directly or interposing a graft. Aortorenal
graft interposition allows better bleeding control, may
accommodate several anatomies, and presents reduced risks
of late aneurysmal degeneration. Its major disadvantage is
that two anastomoses are required for each vessel revascu-
larization, often making this option time-consuming and
occasionally challenging. Alternatively, the use of presewn
aortic branched grafts has the advantage of reducing the
number of total anastomoses to be performed, conse-
quently decreasing operative times.20 However, branches
are presewn to the aortic graft in a ﬁxed position and
may not adapt well to the patient’s anatomy, leading to
subsequent kinking or twisting after viscera derotation.
Finally, customized branched aortic graft may be
employed, in which prosthetic ramiﬁcations are sewn dur-
ing the operation before aortic cross-clamping, taking
into account the variable anatomy of each single patient.21
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able alternative to reduce the visceral ischemia time (but
deﬁnitely increasing total operative time), we found it quite
difﬁcult to predict a priori how the aortic graft will arrange
after the proximal, distal, and intercostal patch anastomoses
are performed.
Previous studies using lactated Ringer solution have
demonstrated the protective effects of selective cold crystal-
loid perfusion on renal function during renal ischemia time.
Perfusion with isothermic and cold blood failed to support
the hypothesis that blood perfusion is more effective than
cold crystalloid in renal protection.2,22 In the current series,
selective renal perfusion was carried out with cold (4C)
crystalloid solution enriched with histidine-tryptophan-
ketoglutarate (Custodiol). We recently found that the use
of Custodiol was safe and provided improved perioperative
renal function compared with lactated Ringer solution.10
Patients with TAAAs often have occlusive disease
involving the visceral branches, either related to atheroscle-
rotic disease or caused by aortic dissection. The presence of
visceral arterial occlusive disease is a signiﬁcant predictor of
renal complications after TAAA repair.23 Furthermore, the
presence of calciﬁcation and thrombus at the origin of the
renal artery is associated with the risk of plaque disruption
and dissection during vessel reattachment, leading to kid-
ney malperfusion.24 Thus, renal artery endarterectomy
may be required before revascularization to remove ostial
plaques and to improve patency rates. This maneuver, how-
ever, has important limitations, including the risk of vessel
thrombosis or distal dissection related to an unsatisfactory
end point. Also, perforation of the friable endarterectom-
ized wall is possible during vessel manipulation or during
the insertion of balloon catheters that are used to deliver
renal perfusion.25
To overcome this problem, several groups started to
use bare stents during TAAA open repair, positioned and
expanded within the renal artery under direct vision, both
to address arterial stenosis or dissection, avoiding endarter-
ectomy, and to tack down an unsatisfactory end point after
visceral endarterectomy.9,26,27
The use of covered self-expanding stents for sutureless
anastomoses in challenging anatomies has been reported
by several authors and in different vascular ﬁelds. Lachat
et al5 ﬁrst reported the concept of a Viabahn-assisted
(W. L. Gore and Associates) sutureless anastomosis in the
so-called VORTEC technique, used for visceral revasculari-
zation during debranching procedures for hybrid complex
aortic repair. The distal end of the covered stent was inserted
over a guidewire into the visceral vessel, whereas the prox-
imal end was sutured end to side directly with the main
feeding graft or ﬁxed into an interposition branch graft on
the main bypass. In 2009, the same group published the re-
sults of 58 patients submitted to hybrid repair of TAAA or
pararenal aortic aneurysm with use of the VORTEC tech-
nique to revascularize 98 renal and 15 visceral arteries,
reporting an overall primary patency rate of 97% at
22 months.28 They also applied this technique to debranch-
ing procedures of supra-aortic trunks, reporting a midterm91% patency rate without implantation-related complica-
tions.29 Similar techniques of sutureless anastomosis with
the Viabahn covered stent graft were used for femoropopli-
teal revascularization by several groups.30,31
The GHVG represents the natural evolution of these
procedures. The tubular heparin-bonded ePTFE graft is
preconnected to the nitinol stent-reinforced section, guar-
anteeing in-line ﬂow while avoiding ﬂow turbulence. The
device was released by Gore in 2012 in the European mar-
ket and approved for hemodialysis access, lower limb
bypass grafting, aortic arch debranching, and visceral revas-
cularization.32 Only three case reports of the use of this
novel graft have been published to date, excluding the liter-
ature regarding hemodialysis access. Levack et al33
reported its use for rapid left common carotid revasculari-
zation during aortic arch debranching. Nigro et al34 used
the GHVG to perform a sutureless distal anastomosis dur-
ing surgery for a high-lying internal carotid artery aneu-
rysm. Bornak et al35 reported a modiﬁed use for celiac
trunk and superior mesenteric artery revascularization dur-
ing a visceral debranching procedure, with satisfying early
patency.
Our study is the ﬁrst, to the best of our knowledge,
reporting the results of the GHVG in renal revasculariza-
tion during TAAA open repair. Our limited experience
showed that this technique was technically feasible in all
planned cases, irrespective of renal artery anatomic location
and quality. As a matter of fact, the GHVG group included
more patients with type B dissection and associated renal
artery stenosis compared with our SRR cohort.
Some of the supposed advantages of this approach
were conﬁrmed during this initial experience, such as the
ability to perform the aortorenal bypass in a timely fashion
(thanks to the distal sutureless anastomosis), reducing
renal ischemia time during cold perfusion. Also, we were
satisﬁed by the high technical success rate in reaching
remote arterial ostia without the need of extensive expo-
sure of the artery (typically of the right renal artery) and
by the aptitude to avoid kinking or twisting of the revascu-
larized vessel (especially the left renal artery) after viscera
derotation (Fig 3). Also, the GHVG performed well in ste-
notic or dissected vessels, allowing simultaneous arterial
ballooning-angioplasty and avoiding the need of additional
surgical (endarterectomy) or endovascular (bare stenting)
procedures. Of course, the use of the GHVG comes at an
added cost to the procedure, but this can be compensated
by the relatively lower use of renal bare stents, as was found
in our experience.
A well-known problem with ePTFE grafts is the poten-
tial for prolonged needle hole bleeding from the anasto-
mosis, which may be exacerbated by heparin, hypothermia,
thrombocytopenia, and coagulopathy in TAAA open repair.
Suture-line bleeding has been reported to potentially
increase operative time, overall blood loss, and risk of infec-
tive complications and may require the use of a variety of
topical hemostatic agents or sealants.36 In our experience,
mild initial bleeding from ePTFE needle holes resolved
spontaneously after a few minutes in most cases. In case of
Fig 3. Computed tomography angiography (CTA) reconstruction
1 month after open thoracoabdominal aortic aneurysm (TAAA)
repair, showing patency of a left aortorenal bypass performed with
the Gore Hybrid Vascular Graft (GHVG).
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compression with surgical gauze and oxidized cellulose
pads. At the same time, complete reversal of heparin and
aggressive transfusions are required to correct thrombocyto-
penia and coagulation derangements.
CONCLUSIONS
In this limited series, renal function appeared to
temporarily decrease during the ﬁrst postoperative days,
consistent with our previously published results10,37 and
with the most recent literature data.12,38 In considering
the perioperative peak decrease of GFR, GHVG patients
seemed to present a lesser grade of renal dysfunction
compared with SRR patients. These data may obviously
be the result of a multimodal approach to preserve renal
function after TAAA open repair, including a number of
intraoperative and postoperative adjuncts, and can be high-
ly inﬂuenced by other confounding factors that are not
addressed by the current group analysis.
The present comparison between GHVG and SRR pa-
tients has to be considered together with its important lim-
itations, related to the small number of cases and to the
relative heterogeneity of considered patients. The groups
were matched with the only purpose of getting an impres-
sion of how the GHVG behaved compared with our histor-
ical cohort. We deﬁnitely cannot draw any conclusionabout a possible relationship between the use of the
GHVG and perioperative renal function preservation on
the basis of these limited data. However, technical feasi-
bility and short-term patency rate of the GHVG for renal
revascularization during TAAA open repair were satisfac-
tory, and we hope that this novel graft will represent an
additional step forward in the ﬁght against perioperative
kidney injury.
This is the ﬁrst report describing renal revascularization
during TAAA open repair with the GHVG. Our initial
results indicate that this technique is feasible also in chal-
lenging anatomies, with several potential technical advan-
tages. Short-term clinical and radiologic outcomes were
satisfactory. Larger series and longer follow-up are needed
to conﬁrm the safety and durability of the proposed
technique.
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